Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Amgen in a research note issued to ...

notably impacting legacy products like Neulasta and Enbrel. The sales of these drugs have eroded due to competitive pricing from biosimilar counterparts. However, Amgen proactively launched its ...